The proximity of UB’s New York State Center of Excellence in Bioinformatics & Life Sciences (CBLS) to dynamic clinical environments and facilities, particularly the world-renowned Roswell Park Cancer Institute, provides the ideal environment for our gifted faculty to collaborate on cancer research projects ranging from discovery based study of the functional role of the p53 family members in squamous cell carcinoma; use of advanced epigenetic lanscape of cancer cells; and translational research targeted on developing predictive screening tools for cancer recurrence and guide antineoplastic therapy to improve treatment outcomes.
This laboratory focuses on understanding the behavior of invasive cancers caused or exacerbated by clinical features of insulin resistance. Our group constantly evaluates drug-drug and drug-disease interactions associated with aggressive tumor phenotypes. Based on these findings, we make treatment recommendations aimed to improve outcomes and prolong survival. Our goal is to develop synergic pharmacotherapy regimens targeted to both phenotype manipulation and tumor kill.
This laboratory is interested in understanding the molecular mechanisms of epithelial tumorigenesis with a specific focus on Head and Neck Squamous cell Carcinoma (HNSCC) and cutaneous SCC. We study the role of p63, a p53 family member using both gain-of-function (transgenic) and loss-of-function (knockout) mouse models and human squamous cancer cell lines. Our goal is to understand how the transcriptional circuitry of the cancer cells is disrupted due to the dysregulated expression of p63. Long term, such studies will likely offer new biomarkers and therapeutic targets for SCC.
This laboratory utilizes state of the art genomic/epigenomic techniques including ChIP-seq, Mnase-seq and ATAC-seq along with custom computational approaches to interrogate the “rules” that dictate transcription factor targeting in an eukaryotic genome and apply the findings towards the study of different cancer types.